

---

# PSYCHOPHARMACOLOGY NEWSLETTER

---

Volume 22, Number 3

Division 28 - The American Psychological Association

Fall, 1989

---

## PRESIDENT'S LETTER

*Robert L. Balster*  
President, Division 28

I am pleased to carry on a recent Division tradition by supplying a regular column to the Newsletter. I thought I would use this occasion to discuss the evolution of the Division's public affairs efforts over the last few years. We have made great strides in a number of areas that can serve as models for the future. In this column and the next, I will give my personal perspective on two of these areas. The opinions are mine, and the facts may not all be correct. This is not intended to be a history, and I have not attempted to acknowledge the contributions of individual Division members and APA staff who played critical roles in these efforts. Rather, my intent is to provide a general overview of what I think I have learned about how we can bring our expertise to bear on public policy issues.

The two issues with which I have been most involved are the NIDA research budget and neurobehavioral toxicity testing. They represent somewhat different public affairs activities. The NIDA budget is an appropriations issue and involves dealing primarily with Congress. Neurobehavioral toxicology testing is a regulatory issue and involves dealing primarily with the administrative branch--in this case the Environmental Protection Agency. In this column I will focus on drug abuse research; next issue, I will consider our efforts in neurobehavioral toxicity testing.

I believe that an important milestone for the Division in the arena of drug abuse research policy was to convince the APA central office that NIDA funded research and other programs that were of critical importance to psychologists. It had been my impression that APA focused its efforts mainly on NIMH, perhaps not surprisingly. I remember very well a meeting held in September, 1985 at APA in Washington of Division 28 representatives Linda Dykstra, John Grabowski, and myself with a number of

*cont. on p. 5*

## \*\*\* ACTION ALERT \*\*\*

In early November, you will receive the annual apportionment ballot from APA. This ballot provides you with 10 votes, which you can either allocate totally to one division or distribute among several divisions. The number of Division 28 members on the APA Council of Representatives is determined by this allocation vote.

Division 28 currently has one representative on Council, but we could lose that representative if Division 28 members neglect to allocate all or at least a portion of their votes to Division 28. Maintaining our voice on Council is one of our main avenues for influencing APA. It is critical that Division 28, along with the other scientifically-oriented divisions, be as strongly represented as possible.

## CHARLES FRANCE RECEIVES YOUNG PSYCHOPHARMACOLOGIST AWARD, 1989

Charles P. France, Ph.D. is the recipient of the Young Psychopharmacologist Award for 1989. He is the seventh young scientist to be distinguished by the award since the inception of the program in 1984.

Dr. France is presently an Assistant Research Scientist in the Department of Pharmacology, University of Michigan, and Adjunct Assistant Professor in the Department of Psychology. He received his undergraduate training at Northland College in Wisconsin and was awarded the B.A. degree in music in 1978. Following graduation, he accepted a position in the Psychiatry Research Unit at the University of Minnesota, where he worked with Drs. Richard Meisch and Marilyn Carroll before beginning graduate school. In 1985, he received the Ph.D. in psychology from the University of Michigan as a student and trainee of Dr. James H. Woods. His doctoral work was based upon laboratory studies on the effects of opioid agonists and antagonists in pigeons. Dr. France then moved to Boston, where he

*cont. on p. 2*

## YOUNG PSYCHOPHARMACOLOGIST (cont.)

worked with Dr. William H. Morse as a Postdoctoral Fellow in the Laboratory of Psychobiology at Harvard Medical School. While in Boston, he conducted research on the behavioral and pharmacological effects of opioid agonists and antagonists in squirrel monkeys and the development of supersensitivity to antagonists.

Dr. France is the recipient of a research grant from the National Institute on Drug Abuse to study the discriminative-stimulus effects of opioid withdrawal in laboratory animals. His address at the APA meeting, entitled "Behavioral Measures of Opioid Dependence and Withdrawal," described studies he has been conducting on the discriminative-stimulus effects of opioid agonists and antagonists in morphine-treated monkeys. An emphasis on the effects of opioids has characterized his research activities since his introduction into the laboratory at the University of Minnesota, and he has now pursued these studies in a variety of animal species, including pigeons, squirrel monkeys and rhesus monkeys.

The Young Psychopharmacologist Award is presented annually by the Psychopharmacology Division of APA under the sponsorship of The Burroughs Wellcome Fund. Selection is based on competitive evaluation of the credentials and research accomplishments of young scientists following their nomination by members of the Psychopharmacology Division. This is the sixth year of sponsorship by The Burroughs Wellcome Fund, an organization that has a long history of support for psychopharmacology and behavioral pharmacology.

## ANOTHER FACE OF CLINICAL PSYCHOPHARMACOLOGY

*Richard Katz*  
CIBA-GEIGY Corporation

Psychopharmacology, by its nature, is a discipline with fuzzy borders. At one end it merges with cellular neuroscience, and at the other with clinical medicine. While many psychologically-oriented psychopharmacologists might position themselves somewhere close to a middle ground, involving preclinical studies of drugs and behavior, it should be realized that at least a few of us have moved closer to the periphery.

I would like to describe one perhaps less-appreciated aspect of our discipline that borders on medical practice. I do so for four reasons. First, it's where I am, and it might be of interest to others to know that psychologists are criti-

cally involved in the drug approval process. Second, I feel this is a case in point (possibly *the* case in point) of psychologists' doing work (that is, the oversight and conduct of clinical studies necessary for drug approval) that broadly and immediately benefits society. Third, insofar as prescribing privileges for psychologists is seen as an issue, this is probably the closest current approximation to that practice that exists. Finally, clinical trials are a legitimate and rewarding research trajectory that a young psychopharmacologist might wish to consider as a career.

### The Drug Approval Process

Prior to the marketing of new drugs, the burden of proof rests with an industrial sponsor to demonstrate that a compound is safe and effective. This is accomplished by a series of around ten to twenty experimental studies in subjects and patients. Typically, we first investigate safety and tolerability in a small number of volunteers and eventually move to an examination of dose effects and efficacy in large multi-center studies.

### The Monitoring Process

Senior study monitors, including psychologists, have been involved in the approval process at many levels of responsibility, including project management, the creation of protocols, the selection of study investigators (some of them also psychologists), compliance oversight, and the eventual interpretation of findings. The job description to some degree varies, company by company.

### Involvement of Psychologists

Normally the conduct of clinical trials is the purview of physicians, but interestingly, psychologists have also been involved, particularly in trials of numerous psychotropic drugs. To provide a few recent examples, such trials include tests of the first compound for obsessive-compulsive disorder, new antidepressants, the first non-sedating anxiolytic, and a variety of memory-enhancing drugs. We have helped to evolve some of the instruments and testing methods used in these trials.

### The Lessons

To someone who began his career with electrodes, brain stimulation, and cumulative recorders, a number of lessons are signal. First of all, the basic skills that come with graduate education in psychopharmacology are broadly applicable. It takes the same concern and methodological rigor to do a radioimmunoassay or a factorial study of a memory enhancing drug in rats as it does to carry out an

*cont. on p. 5*

## MINUTES, DIVISION 28 ANNUAL BUSINESS MEETING, AUGUST 11, 1989

Alice M. Young

Member-at-Large, Division 28

1. President Linda Dykstra convened the meeting at 5:05 p.m., with approximately 30 Division members attending. Minutes of the August, 1988 Business Meeting, as published in the Fall 1988 *Newsletter*, were approved.

2. President Dykstra announced the results of the 1989 Division 28 elections:

President-elect: Klaus Miczek

Member-at-large: Robert Sprague

3. Membership chair Steve Fowler welcomed 10 new Fellows of Division 28:

|                   |                   |
|-------------------|-------------------|
| Nancy Ator        | Charles Ksir      |
| Debra Ann Bennett | Melvin Lyon       |
| Salvatore Cianci  | Paul R. Sanberg   |
| William Miles Cox | Jalie A. Tucker   |
| John Glowa        | Rudy E. Vuchinich |

Steve also reported that approximately 50 APA members applied for membership in Division 28 this year. He noted that the total membership in the Division decreased by approximately 5% this year. Finally, he encouraged Division members to submit names of potential new Fellows.

4. Treasurer Jack Henningfield reported that our income for fiscal year 1988 was approximately \$12,000, and our expenses were approximately \$11,000. Our largest expenses continue to be the newsletter and the annual convention. Jack estimated that the \$5 dues increase that went into effect this year will increase our annual income by about \$4,000. President Dykstra noted that the Division's Executive Committee has decided to use any increase in income to enhance our advocacy efforts.

5. Hugh Evans presented a report from the Division's Animal Research Committee. During the past year, the committee published an article on psychological well-being of primates (Woolverton et al., *Life Sciences*, 44:901-917, 1989), prepared a bibliography on animal care issues that is available to Division members upon request, and submitted comments on the proposed revisions in the USDA animal welfare regulations. During the upcoming year, the committee plans work on continuing education for veterinarians

and on a brochure on the role of animal research in drug abuse research. During discussion, Jim Woods noted that he has been approached to prepare a brochure on the role of animal research in drug abuse and mental health; Jim recruited Division members to work on this project.

6. Bob Balster, Public Affairs Officer, reviewed the Division's public policy activities. These continue to include lobbying on behalf of animal research, federal research budgets for drug abuse, and working with APA Central Office Staff on issues of interest to Division members.

7. President Dykstra reviewed the Division's relationship with APS. We have continued our status as an Organizational Affiliate of APS, and the Executive Committee appointed Don Overton as our Liaison to APS for 1989-91. The Executive Committee continues to recommend that our members consider joining APS.

8. President Dykstra thanked Barb Slifer, Program Chair, for organizing an excellent convention program for New Orleans. Linda then introduced our Program Chair for the 1991 meeting in Boston - Warren Bickel, Dept. of Psychiatry, University of Vermont.

9. Council representative John Grabowski outlined the major issues considered by the Coalition of Academic and Applied Psychology and by the APA Council at their initial meetings of the convention. See John's article elsewhere in this issue of the *Newsletter* for a full report of these meetings.

10. President Dykstra outlined several issues:

10.1. The APA Science Directorate continues publication of its Science Agenda, a newsletter outlining the activities of the Science Directorate. Division members who are not receiving the Agenda can request it from the address listed elsewhere in this *Newsletter*.

10.2. Division 9 (SPSSI) is forming a Coalition of Psychologists in the Public Interest, with plans to make substance abuse one of the Coalition's key issues in the upcoming year. SPSSI asked that a spokesperson from Division 28 attend a planning meeting at the convention. Linda asked Council representative John Grabowski and Past-president George Bigelow to attend as our representatives.

10.3. The Executive Committee has appointed Marlyne Kilbey chair of an ad-hoc committee to explore issues surrounding prescription privileges for

*cont. on p. 4*

## BUSINESS MEETING MINUTES (cont.)

psychologists. Linda noted that the APA Practice Directorate is interested in this issue. As a first step, the Executive Committee has separated the issue of "should psychologists have prescription privileges" from the issue of "what training curriculum will be needed to prepare psychologists for any prescription privileges." The ad-hoc committee will examine this latter question and has been given a budget of \$1000 over two years.

11. Ron Wood gave a brief report of activities of the Neurobehavioral and Toxicology Test Standards Subcommittee and thanked the Division for its continuing support.
12. President Dykstra and President-elect Bob Balster presented the Executive Committee's slate of officers for the 1988 Division elections. Additional nominations were made from the floor. The following members of the Division will stand for election:

President-elect:

Chris-Ellyn Johanson  
Maxine Stitzer  
Ronald Wood

Member-at-large:

Marilyn Carroll  
Donald Cherek

Council representative:

Stephen Fowler  
M. Marlyne Kilbey

13. The following members have agreed to accept appointments to the Executive Committee:

Program Chair, 1991: David Penetar

APS Liaison (1989-91): Donald Overton

ASPET Liaison (1989-91): to be named

Public Affairs Officer (1989-91): Chris-Ellyn Johanson

Public Information Officer (1989-91): John Grabowski

14. The Division thanked Linda Dykstra for her leadership. Incoming President Bob Balster welcomed any suggestions for future activities of the division.

15. There being no additional business, the meeting was adjourned at 6:00 p.m.

## APA COUNCIL MEETING: AUGUST, 1989

John Grabowski

Council Representative, Division 28

This report summarizes council and related meetings occurring at the Annual Meeting of the APA, New Orleans.

The coalition of Academic, Scientific and Applied Psychology met on Wednesday. Impending Council votes on issues were discussed. APA Treasurer and President Elect Spielberg attended and discussed: 1. the new APA building to be built near Union Station in D.C., with occupancy in two years; 2. division users' fees for some central office activities--the argument being that since only 50% of membership belong to divisions, extra service for divisions should be paid by divisions, a notion not likely to survive; 3. APA's willingness to help divisions in the development of new journals; and 4. APA's development of a book series (divisions/members may wish to approach APA concerning items they wish to publish).

Council (with its 113 members) met on Thursday (August 10) and Sunday (August 13). Items of business were dealt with as follows:

*Approvals included:* 1. Establishment of a Division of Peace Psychology; 2. Fair testing practices; 3. Enhanced (but still lax) residency requirements for Ph.D.; 4. Support of UN Convention on Rights of the Child; 5. Education Directorate; 6. Election to Fellow rules; 7. Affirmative action efforts; 8. Item on Psychological Issues in the Abortion Debate (essentially a *data based* pro-choice position); U.S. support of UNESCO.

*Items deferred to February meeting included:* 1. Conflict of interest provisions for Board and Council members.

The other major item of interest is the APA Budget. *The proposed and approved* 1990 draft budget was balanced at \$35.7 million. The projected Science Directorate budget for 1990 is \$2.45 million (minus revenues of \$224,000 = \$2.2 million approximate). This was an increase from \$2.02 (1989) and \$2.09 (1988) million.

Dr. Spielberg is the President-Elect of APA, and Kimble came in second, using the Hare vote counting system. That both outpolled several more traditional clinical candidates was reassuring. At the Coalition meeting Kimble agreed to run again next year. It is expected that with Fowler (Past President and now Chief Executive Officer of the APA) and Matarazzo (and next Spielberg)

*cont. on p. 5*

## COUNCIL MEETING (cont.)

as current President, there will be good support of the interests of science and the Science Directorate.

Recommendations were made to Dr. Fowler by each of several separate working groups on questions concerning: 1) relations to APS; 2) improvements in APA's relation to Division activities; and 3) suggestions concerning the APA Centennial in 1991-92. Concerning item #1, the bulk of suggestions were that liaisons should be established across levels between APA and APS, with attention to particular conflicting interests. Strategies for having Directorates attend to divisional needs were recommended, particularly when issues cross the Directorates' purviews. A variety of suggestions were made concerning cooperation between specialty societies and regional psychological associations, and means to "promote/publicize" the efforts and contributions of psychology as a science and profession were proposed (including an effort afoot to have a U.S. postage stamp issued). Send centennial suggestions to Fowler or Spielberg, or to your Divisional president (28 = Robert Balster).

There was a generally conciliatory mood at APA. A Blue Ribbon panel headed by Frances Horowitz reported that there is substantial effort in the APA on behalf of science; she further noted that there must be an effort both to sustain this activity and to eliminate the misperception that science is not served.

Please get in touch with me by letter or telephone if you have questions concerning budget or actions taken at the Council meeting, or views and suggestions on current or new directions for the APA. Substantive comments will be delivered to the Council of Representatives meeting in January, 1990. (Address and phone on p. 11.)

## CLINICAL PSYCHOPHARM (cont.)

adequate and well-controlled clinical study. The same rules apply--you need to blind, to randomize, and to standardize. Equally, the modes of interpretation that apply to preclinical data may apply clinically. This is not to say that clinical subjects are large rats or pigeons. New ethical concerns apply more immediately, and should, and do, supersede questions of efficacy. A clinical trial is characterized by ethical tensions that apply to a significantly lesser degree in preclinical studies.

### Significance

Many of us have continued to maintain a research

presence in journals and at meetings. Several companies now encourage some affiliation with local universities on a *pro bono* basis.

Particularly when experimental psychology is attempting to justify the role it plays for society, the creation of new medicines to aid in the treatment of crippling diseases should be viewed as a significant activity. I would be curious and interested to hear from other psychologists who are involved in the clinical trials process.

## PRESIDENT'S LETTER (cont.)

APA staffers. Virginia Holt was the key APA liaison for that meeting. John, who was working at NIDA at that time, was able to tap the Institute's computers to reveal that psychologists were the PI's on about 40% of NIDA's grants and played key roles in many others. It was also pointed out that two of our Division members, Bob Schuster and Conan Kornetsky, were under serious consideration for the position as Director of NIDA, and that there were a number of other Division members in key positions in the Institute. At about this same time, Division member Marian Fischman was appointed to the APA Committee on Research Support, where she was also able to bring drug abuse research issues to the attention of APA. Finally, drug abuse was becoming a national priority, capturing an increasing amount of attention from government and media. This confluence of events was very helpful in establishing drug abuse research and NIDA as important priorities for APA central office public affairs efforts.

Among the first things that APA did in 1985 was to support strongly the nominations of Bob Schuster and Conan Kornetsky for NIDA Director using material drafted by the Division; and as we know, Bob was the eventual choice. With Bob Schuster as Director and other Division members (including John Boren, Sam DiMenza, Irv Geller, Steve Gust, Roy Pickens, Barbara Ray, and Mike Walsh) in key staff positions at NIDA, the Division and APA have excellent access to the Institute. I have become convinced that one of the important ingredients of successful advocacy for a federal agency is to have knowledgeable contacts within the agency to provide information on its plans and operations. Unfortunately, Lisa Shugar, the APA staff person on drug abuse issues who had established many contacts within the Institute and Congress, has recently resigned. It will be critical to replace her expertise at APA.

One of the major issues related to NIDA that requires constant attention is the annual appropriation. It may be instructive to consider how the NIDA appropriations

*cont. on p. 6*

## PRESIDENT'S LETTER (cont.)

process takes place to see where opportunities exist to have the Division's interests reflected in the NIDA budget. As most of you know, the Federal fiscal year begins October 1; the year starting October 1, 1989 is FY 1990. The process begins with the Institute developing a budget request. There are two sets of figures that emerge from this process. The first set is often referred to as the "professional judgment" budget. This is a wish list by the Institute, which typically allows for orderly growth in existing programs as well as provides funds for some new initiatives. The professional judgment budget often serves as a reasonable goal for lobbying groups advocating increased support for research. Another important set of figures is usually referred to as the President's budget, which represents the current administration's actual proposed appropriation. In my experience, this is generally quite a bit lower than the Institute's wish list. I have not figured out a way to influence the President's budget proposal, but perhaps some ways can be found.

Congressional action on the NIDA appropriation begins with hearings by the relevant subcommittees of the Appropriations Committees of the House and Senate. They are the House and Senate Appropriations Subcommittees on Labor-HHS-Education. These are key committees as far as NIDA is concerned. It is important to get to know the members of these Committees and their staffs. Division members who live in the states and/or districts with representation on these committees are in a particularly good position to make contacts and have their views known. I have recently obtained a computer listing from APA of Division members who have representation on these committees, and I hope to begin to enlist even more help from these individuals over the next year. Typically, APA arranges to provide testimony at the subcommittee hearings and works in other ways to inform members of Congress and their staffs of our concerns for research support.

This is one area where a large professional society with relevant experience is of immeasurable help in arranging for contacts among Congresspersons, their staffers, and psychologists with interests in legislation. It is an ongoing process, requiring attention not only during the appropriations process but also during the rest of the year. APA is happy to arrange for visits between psychologists and government officials and engages in many activities to keep our "agenda" in front of Congress. One of the important ways they can do this is by serving as a technical resource, helping to identify expertise among APA members that can be brought to bear on issues of national concern. (Space does not permit me to illustrate the many opportunities the

Division has had to provide important expertise.) APA also arranges for Division members to give briefings and speeches in the Washington area, and for visits to research laboratories by participants in the legislative process. Finally, APA has taken a leadership role in both the Alcohol and Drug Coalition and the Federation of Behavioral, Psychological and Cognitive Sciences. These are coalitions of professional societies with similar public affairs agendas that also work in support of drug abuse research.

The final result of the subcommittee hearings is a "marked up" appropriations bill from each branch of Congress. These figures are usually referred to as the House and Senate "mark" and often differ from the President's budget. Lately, Congress has increased the NIDA budget over the President's recommendations. These appropriations bills are eventually passed by the full Appropriations Committees and then differences are reconciled in Conference Committee. Consequently, representatives on the full Appropriations Committees are also important targets for lobbying efforts. Lately, Congress has been unable to pass appropriations bills before the start of the fiscal year, resulting in the necessity of continuing resolutions. This causes the Institute problems, since it must begin to fund programs without a final budget, and little time remains to begin new initiatives called for in the budget before the end of the fiscal year.

So what does all this have to do with psychopharmacology research? Obviously, the final NIDA budget will have a great deal to do with which new and competing grant and contract proposals can be funded. A "continuing services" budget essentially means that new grant applications and competing renewals will need to be funded from the same pot of money. As most of you know, in recent years NIDA's extramural research budget has increased quite dramatically, allowing the Institute to begin new programs and fund new applications. Nevertheless, many believe that the nation's research effort in the area of drug abuse is still insufficient to meet the problems we face. The President's FY 1990 budget recommendation for NIDA does not provide for significant increases. The House mark was a bit higher; as of this writing, the Senate has not as yet marked up its appropriation bill. Given the concerns in Washington about the drug abuse problem, it is possible that increased appropriations for NIDA's research effort may be forthcoming from this Congress, although the President's Drug Abuse Control strategy placed a very low priority on research.

In addition to having an impact on the amount of NIDA appropriations, we can influence NIDA's research  
*cont. on p. 7*

## PRESIDENT'S LETTER (cont.)

efforts in the report language that accompanies the appropriations bill. This report language establishes research priorities as members of Congress see them. Appropriations Subcommittee staffers often call upon the expertise of professional societies and others who have a strong interest in the activities of NIDA to help identify new priorities for research. APA and the Division have recently played a role in this process. It is also important to make certain that technicalities of the appropriations legislation do not have a negative impact on research. This sometimes takes the form of specific "set-asides" for special programs within the Institute, where funds that would normally be used for basic research are earmarked for special areas. Depending upon what these areas are, these set-asides and their specific provisions can have a major impact on the priority placed upon psychological research in the Institute.

Another way that public policy on drug abuse research is determined is in the composition of NIDA's Council, study sections, and other advisory committees. APA and the Division have sought to nominate Division members to these important committees and continue to seek individuals interested in this type of consulting activity.

Financing the nation's drug abuse effort is a major issue in Washington at this time, so by the time you read this letter, there could be some dramatic changes in the NIDA budget for FY 1990. My major purpose in writing this column has been to give you my perspective on the Division's increasing involvement in public policy in the drug abuse research area. Indeed, I have not had the space to review all the areas where Division members are active. Most importantly, I believe that the level of our involvement with NIDA can serve as a model for what can be done with other Institutes and Federal agencies. With a few isolated exceptions, the Division has had a much less visible role in influencing research support in other areas. Other agencies that fund psychopharmacology research that we need to pay more attention to include NIMH, NIAAA, OSAP, NIEHS, NICHD, NINDS, NIA, and EPA. I urge you to familiarize yourself with public policy issues relating to support of research in your areas of expertise. Phone or write me or Chris-Ellyn Johanson, our Division Public Affairs Officer, or APA Science Directorate Staff with your interests or concerns. Get in touch with staff persons in other societies you may belong to in order to determine their involvement in research funding in your area. Use your contacts with the press to bring up the need for research support. Finally, interact with your Congressional representatives and their staff members on appropriations bills. An important component of the resolution of many of the problems we face is continuing research and

development. It is essential that, as scientists, educators, and concerned clinicians, we get involved in seeing that the financial resources needed for this effort are forthcoming.

## CALL FOR NOMINATIONS

The APA Publications and Communications Board has opened nominations for the editorship of the *Journal of Experimental Psychology: Animal Behavior Processes* for 1992-1997. Candidates must be APA members and should be available to start receiving MSS on 1/1/91. Submit nominations by 1/15/90 to J. Bruce Overmier, Chair, Editor Search Committee, Department of Psychology, University of Minnesota, 75 E. River Road, Minneapolis, MN 55455.

## OPEN POSITIONS

**Postdoctoral Scientist:** Postdoctoral scientist position open at Lilly Research Laboratories for a behavioral pharmacologist. Lilly Research Laboratories is a Division of Eli Lilly and Company, a major pharmaceutical company. The postdoctoral scientist will work with Lilly scientists in the areas of operant behavior and behavior elicited by various stimuli to study agonists and antagonists of excitatory amino acids, serotonin, neuropeptide, and opioid receptors. Postdoctoral appts. are available for 1 year, renewable for a 2nd year by mutual agreement. Applicants should send c.v., including "program of interest," to: John W. Crooks, Manager, Ph.D. Recruitment (PSP), Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285.

**Ph.D. Neuropharmacologist - To \$65K:** Requires 3-7 years experience in operant models, behavioral paradigms, and dopaminergic receptor functioning pertaining to antipsychotic therapy. Supervision of your own R&D lab! **BS/MS Pharmacologists - To \$37K:** Seven positions for experienced neurobiologists and cell biologists to work with binding techniques and 2nd messenger research. HPLC and epithelial tissue culture highly desirable. We are the most prestigious biomedical/pharmaceutical research and development corporation in the world. Our headquarters, located in suburban Philadelphia, offers challenging opportunities, promotability, and job stability far above our competitors. Send your C.V. for confidential reply to Lance Converse, Department S-89, 40 Morris Avenue, Bryn Mawr, PA 19010 or call 215-520-0100.

**Postdoctoral Fellow/Research Associate:** At the Johns Hopkins University School of Medicine. Develop and implement human behavioral pharmacology research, both laboratory and applied, related to drug abuse treatment. Stimulating and productive environment. Multiple openings; projects include: (1) studies of both behavioral and pharmacological drug abuse treatment interventions (contingency management, buprenorphine, methadone); (2) human laboratory and outpatient treatment studies of cocaine's interaction with potential treatment drugs; (3) studies of opioid clinical pharmacology and physical

dependence, especially relating to buprenorphine as a drug abuse treatment; (4) studies of AIDS risk behavior and psychiatric disorders; and (5) assessment and treatment of personality disorders in drug abusers. Immediate and continuing position availability. Ph.D. in experimental or clinical; research experience desirable. Stipend: USPHS levels, based on experience, some flexibility. Minorities encouraged to apply. Persons selected will work with faculty in all aspects of designing, planning, conducting, supervising, analyzing, and publishing clinical research. Excellent opportunity for clinical research productivity. Send letter indicating areas of interest, c.v., and phone numbers of 3 references to: George E. Bigelow, Ph.D. or Maxine L. Stitzer, Ph.D., Behavioral Pharmacology Research Unit, D-5-West, Psychiatry, Johns Hopkins/Key Med. Center, 4940 Eastern Ave., Baltimore, MD 21224, (301) 550-0035.

**Research Associate:** Position is available beginning in late Fall in the Department of Psychiatry at the Uniformed Services University for studies on the behavioral properties of psychoactive drugs related to their abuse. Investigations include assessments of the reinforcing and discriminative stimulus properties of stimulants and sedatives in humans. A Ph.D. in the behavioral sciences is required with 2-3 years of post-doctoral experience. Recent graduates will be considered. It is desirable but not essential that the applicant has some experience working with humans in an experimental setting and has a knowledge of the area of behavioral pharmacology or behavioral analysis. Salary is commensurate with experience and eligible candidates will be considered for an assistant research professor position. Applicants should send a curriculum vitae, recent publications, and three references (with addresses and telephone numbers) that can be contacted to: Chris-Ellyn Johanson, Ph.D., Department of Psychiatry, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814.

**Assistant Professor:** Primary responsibility will be to collaborate in the conduct of a program of research in the area of stimulus effects of drugs. Qualifications include 2-4 years postdoctoral experience, published research in human and animal behavior, interest in preclinical psychopharmacology, high level of expertise in computer programming for data reduction and laboratory process control, experience in laboratory development and management. Ph.D. in experimental psychology or pharmacology preferred. This is a non-tenure track position supported by research grant funds. Send resumes to: Donald Overton, Psychiatry Department, 5-OPD, Temple Medical School, Philadelphia, PA 19140.

**Postdoctoral Research Fellowships in Human Behavioral Pharmacology:** Applicants are being sought for two positions in the Substance Abuse Research Center (SARC), Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at Houston. SARC facilities include preclinical research laboratories for rodent and primate research, the Human Behavioral Pharmacology Laboratory (HBPL), and the Addictive Behaviors Clinic (ADC). SARC researchers consist of six full-time faculty, two research associates and a NIDA postdoctoral fellow; additional faculty are being recruited. Position #1 in HBPL would involve collaboration on behavioral and drug studies of human multioperant responding. Position #2 in ADC/HBPL would involve collaboration on studies of behavioral and pharmacological inter-

vention for the treatment of opiate and cocaine abuse and initiation of human drug self-administration studies. Development of one's own research interests would be encouraged, but collaboration on existing projects would be expected. Background in the experimental analysis of behavior highly desirable, as well as computer programming experience. Interested persons should send a c.v. and outline of previous experience and research interests to: Position #1 - Don R. Cherek, Ph.D.; Position #2 - John Grabowski, Ph.D., Department of Psychiatry and Behavioral Science, Substance Abuse Research Center, University of Texas Health Science Center, 1300 Moursund, Houston, Texas 77030, (713) 792-7925.

**Postdoctoral Research Fellowship:** A two year postdoctoral fellowship is available starting October, 1989 at the University of Vermont. The fellow's primary responsibility will be to assist in the development and implementation of studies investigating the efficacy of behavioral treatments for cocaine dependence. Opportunities for conducting laboratory human behavioral pharmacology studies are also available. Doctorate in psychology or related field is required. Salary is competitive. Send letter of interest, VITA, and names of three references to: Stephen T. Higgins, Ph.D., Department of Psychiatry, Human Behavioral Pharmacology Laboratory, University of Vermont, 1 South Prospect Street, Burlington, VT, 05401, (802) 656-4560.

**Associate Professor in Biological Psychology:** The Biological Psychology Ph.D. Program and the Oklahoma Center for Alcohol and Drug-Related Studies announce the availability of a tenure-track faculty position. Applicants should have Ph.D. in psychology, pharmacology, or related field and be proficient in human psychopharmacological research that focuses on cognitive processes, neuropsychology, CNS electrophysiology, and/or addictive disorders. Position will entail graduate level teaching, supervision of pre- and post-doctoral research, and developing laboratories and funding for research projects. Location of the Ph.D. program and the Center within the Department of Psychiatry and Behavioral Sciences on the University of Oklahoma Health Sciences Center campus affords extensive opportunity for multidisciplinary collaboration with other basic and clinical scientists. Since its inception in 1966, the doctoral program has trained 66 Ph.D.'s and 28 post-doctoral fellows. The Center consists of 5 senior scientists and 18 adjunct scientists, fosters a wide variety of alcohol and drug research, and currently enjoys a significant amount of local and federal support for its research and teaching activities. Salary, fringe benefits, and research support commensurate with experience. Applications will be considered until position is filled. Send letter of interest, C.V., and names/addresses of 3 references to: Frank A. Holloway, Ph.D., Chair, Search Committee, University of Oklahoma Health Sciences Center, P.O. Box 26901, Research Building, Room 306-R, Oklahoma City, OK, 73190-3000, (405) 271-2011. *The Univ. of Oklahoma is an Affirmative Action/Equal Opportunity Employer.*

## EQUIPMENT EXCHANGE

**BRS DIGI-BIT MODULES.** Boxes and boxes of these classic modules, as well as card files and power supplies, available to any laboratory that will pay shipping charges. Call Don Overton (215) 787-1534.

## STUDENT MEMBERS OF DIVISION 28

Division 28 is recruiting new student members. If you train students in psychopharmacology, encourage them to become a student member of Division 28. Student members of the Division receive the Newsletter and are welcomed in the Division Hospitality Suite at the APA Annual Convention. Please send the names and addresses of your trainees to Membership Chair Steven Fowler (Department of Psychology, University of Mississippi, University, MS 38677), or have them contact Steve directly.

## FELLOW STATUS IN DIVISION 28

The Executive Committee of Division 28 seeks nominees for Fellow status in the division. Any members who have made outstanding contributions to psychopharmacology are eligible for nomination. If you would like to be considered for fellow status, or if you know individuals who you believe are appropriate for this APA honor, please send a copy of the c.v. to the Division membership chair:

Stephen C. Fowler, Ph.D.,  
Department of Psychology  
University of Mississippi  
University, MS 38677

## ELECTION RESULTS

President-Elect: Klaus Miczek  
Member-at-Large: Robert Sprague

President Dykstra and the members of Division 28 thank all candidates for their active participation in Division affairs.

## 10 NEW FELLOWS IN DIVISION 28

Effective January 1, 1990, 10 members (3 women and 7 men) of Division 28 will become Fellows of the Division. We congratulate them and commend them for their outstanding research and professional contributions.

Nancy Ator, Ph.D.  
Debra Ann Bennett, Ph.D.  
Salvatore Cianci, Ph.D.  
W. Miles Cox, Ph.D.  
John R. Glowa, Ph.D.  
Charles Ksir, Ph.D.  
Melvin Lyon, Ph.D.  
Paul R. Sanberg, Ph.D.  
Jalie Tucker, Ph.D.  
Rudy Vuchinich, Ph.D.

---

## NEWSLETTER AFFILIATES

At its August 1989 meeting the Division 28 Executive Committee established, on a trial basis, a new category of association with the Division. Termed "Newsletter Affiliate", this category of affiliation with the Division does not require membership status in APA. By completing and returning the following form, an individual interested in psychopharmacology becomes a Newsletter Affiliate and receives the Division 28 Newsletter free.

(Please type or print)

Name: \_\_\_\_\_

Institution, Organization, or University: \_\_\_\_\_

Mailing address: \_\_\_\_\_

Return to:

Stephen C. Fowler, Ph.D.  
Membership Chair, APA Division 28  
Department of Psychology  
University of Mississippi  
University, MS 38677

## APA CONVENTION '90--BOSTON

Warren K. Bickel  
Program Chair, 1989

Notwithstanding the common response of Bostonians to a request for directions ("You can't get there from here!"), I hope that all Division 28 members will be getting to the APA convention and make inroads into what could be an exceptional program.

The general "Call for Papers" from APA will be published in the October Issue of the Monitor. The formal submission deadline to the Division program chair is December 15. The materials required include the 1,000 word summary (3 copies) and abstract typed within a 5" x 5" space (4 copies). The abstracts will once again be published in *Pharmacology Biochemistry and Behavior*.

At this time, we do not yet know what the topics for the Science Weekend are going to include. We do know, however, that there will be two Mini-Convention topics that will be of interest to many members of Division 28. The first is "Substance Abuse and Violence" and the second is "Impact of the Media on Critical Social Issues." Our participation in these mini-conventions can benefit the Division through additional program time, distribution of separate program announcements, and publicity and exposure to wider audiences.

Formal submissions should be sent to:

Warren K. Bickel  
Department of Psychiatry  
University of Vermont  
1 South Prospect St.  
Burlington, VT 05401

## NAMES AND ADDRESSES:

Robert L. Balster, Ph.D.  
Dept. of Pharmacology  
Medical College of Virginia  
Box 613  
Richmond, VA 23298  
(804) 786-8402

Herbert Barry, Ph.D.  
Department of Pharmacology  
University of Pittsburgh  
1110 Salk Hall  
Pittsburgh, PA 15261  
(412) 648-8563

Suggestions for symposia, invited speakers, or questions can be addressed to myself (802) 656-4650.

## APA RESEARCH GUIDELINES AVAILABLE

The APA has developed guidelines for psychologists working with drugs and those working with humans or animals in their research. Single copies of the "Guidelines for the Use of Drugs in Research by Psychologists" and the "Guidelines for Ethical Conduct in the Care and Use of Animals" may be obtained at no charge from the Science Directorate, APA, 1200 Seventeenth St. NW, Washington, DC 20036. Copies of "Ethical Principles in the Conduct of Research with Human Participants" can be obtained from the APA Order Department, PO Box 2710, Hyattsville, MD 207784. The list price is \$8.50; the cost to members and affiliates is \$6.50.

## CENTENNIAL CELEBRATION

Herbert Barry  
Centennial Liaison Officer

The APA centennial celebration will begin in August, 1991, at the annual meeting in San Francisco, but most of the festivities will take place at the annual meeting scheduled for August, 1992 in Washington, DC. The Division 28 Centennial Program Chair for the 1992 meeting will be selected in 1990. Because of the divisional structure of APA (which is not shared by APS), this event offers a unique opportunity to focus on the history of psychopharmacology as a discipline. We encourage you to think about the kind of oral and written presentations that might best convey something about the field and to submit for our consideration any historical information you may have.

## OFFICERS AND COMMITTEE CHAIRS

Warren K. Bickel, Ph.D.  
Department of Psychiatry  
University of Vermont  
1 S. Prospect Street  
Burlington, VT 05405  
(802) 656-7889

Larry D. Byrd, Ph.D.  
Yerkes Regional Primate Research Center  
Emory University  
Atlanta, GA 30322  
(404) 727-7730

Linda A. Dykstra, Ph.D.  
Department of Psychology  
University of North Carolina  
Chapel Hill, NC 27514  
(919) 962-6595

Hugh L. Evans, Ph.D.  
Institute of Environmental Medicine  
550 First Avenue  
New York, NY 10016  
(914) 351-4249 or (212) 340-7300

Steven C. Fowler, Ph.D.  
Department of Psychology  
University of Mississippi  
University, Mississippi 38677  
(601) 232-7383

John Grabowski, Ph.D.  
Department of Psychiatry and Behavioral Sciences  
U.T. Health Science Center  
1300 Moursund, Room 341  
Houston, Texas 77030  
Telephone: (713) 792-7925

Sharon M. Hall, Ph.D.  
CSBS Health Psychology, Room 204  
University of California, San Francisco  
Box 8044  
San Francisco, CA 94143  
(415) 476-7574 or 681-8080 (ext. 574)

Jack E. Henningfield, Ph.D.  
NIDA Addiction Research Center  
P.O. Box 5180  
Baltimore, MD 21224  
(301) 955-7508

Stephen T. Higgins, Ph.D.  
Department of Psychiatry  
University of Vermont  
1 S. Prospect Street  
Burlington, VT 05405  
(802) 656-7884

Chris Ellyn Johanson, Ph.D.  
Uniformed Services University of the  
Health Sciences  
430 Jones Bridge Road  
Bethesda, MD 20814  
(202) 295-0972

Marlyne M. Kilbey, Ph.D.  
Department of Psychology  
Wayne State University  
71 W. Warren  
Detroit, MI 48207  
(313) 577-2802

Klaus A. Miczek, Ph.D.  
Department of Psychology  
Tufts University  
Medford, MA 02155  
(617) 381-3414

Donald A. Overton, Ph.D.  
Departments of Psychology and Psychiatry  
Weiss Hall, Temple University  
13th & Columbia Ave.  
Philadelphia, PA 19122  
(215) 787-1534

Cynthia S. Pomerleau, Ph.D.  
Department of Psychiatry/Behavioral Medicine  
The University of Michigan  
900 Wall Street  
Ann Arbor, MI 48105-0722  
(313) 764-7152

Barbara L. Slifer, Ph.D.  
Department of Psychology  
University of New Orleans/Lakefront  
New Orleans, LA 70148  
(504) 286-6771

Robert L. Sprague, Ph.D.  
Institute for Child Behavior & Development  
University of Illinois  
51 Gerty Drive  
Champaign, IL 61820  
(217) 333-4123

Ronald W. Wood, Ph.D.  
Institute of Environmental Medicine  
New York University  
550 First Avenue  
New York, NY 10016  
(914) 351-4249

Alice M. Young, Ph.D.  
Wayne State University  
Department of Psychology  
71 West Warren Avenue  
Detroit, MI 48202  
(313) 577-3290

## DIVISION 28 OFFICERS

| <i>Elected:</i>        |                   | <i>Term on Council</i> |
|------------------------|-------------------|------------------------|
| President              | Robert L. Balster | 9/88-8/91              |
| President-Elect        | Klaus Miczek      | 8/89-8/92              |
| Past-President         | Linda Dykstra     | 9/87-8/90              |
| Council Representative | John G. Grabowski | 2/88-2/91              |
| Members-at-large       | Sharon M. Hall    | 9/87-8/90              |
|                        | Alice M. Young    | 9/88-8/91              |
|                        | Robert Sprague    | 8/89-8/92              |

### *Appointed:*

|                            |                      |           |
|----------------------------|----------------------|-----------|
| Treasurer                  | Jack E. Henningfield | 8/88-8/91 |
| Secretary                  | Stephen T. Higgins   | 8/88-8/90 |
| Program Chair, 1990        | Warren K. Bickel     | 9/88-8/91 |
| Past-Program Chair         | Barbara L. Slifer    | 9/87-8/90 |
| Incoming Program Chair     | David Penetar        | 8/89-8/92 |
| Newsletter Editor          | Cynthia S. Pomerleau | 5/88-8/91 |
| Membership Chair           | Stephen C. Fowler    | 8/88-8/91 |
| CPDD Liaison               | Robert L. Balster    |           |
| Public Information         | John G. Grabowski    | 6/87-8/91 |
| ASPET Liaison Officers     | TBA                  |           |
| APA Public Affairs Liaison | Chris Johanson       | 8/89-9/91 |
| APS Liaison                | Donald Overton       | 8/89-9/91 |
| Committee on Nominations   | Larry D. Byrd        | 8/89-8/91 |

## DIVISION 28 OFFICERS (cont.)

|                               |                |           |
|-------------------------------|----------------|-----------|
| NTTSC                         | Ronald W. Wood | 8/89-8/91 |
| Committee on Animal Research  | Hugh L. Evans  | 8/89-8/91 |
| Committee on Prescript. Priv. | Marlyne Kilbey | 8/89-8/91 |
| Centennial Officer            | Herbert Barry  | 8/89-8/91 |

## SUBMISSION OF COPY FOR THE NEWSLETTER

Readers are invited to submit articles and information of general interest to Division 28 members. Copy may be submitted typed double-spaced on standard bond paper or word-processed on IBM-compatible equipment; be sure to include hard copy in case the diskette is damaged in the mail. Submit materials to:

Cynthia S. Pomerleau, Ph.D.  
Behavioral Medicine Program  
University of Michigan Department of Psychiatry  
Riverview Building, 900 Wall Street  
Ann Arbor, MI 48105-0722  
(313) 764-7152

The Newsletter is published on a quarterly basis and will appear 4-6 weeks after each deadline. Deadlines for submission of materials are:

Fall issue: September 15      Spring Issue: March 15  
Winter issue: December 15      Summer Issue: June 15

Cynthia S. Pomerleau, Ph.D.  
Editor, *Division 28 Newsletter*  
Behavioral Medicine Program  
University of Michigan Department of Psychiatry  
Riverview Building, 900 Wall Street  
Ann Arbor, MI 48105



"We'll pack ANYTHING  
and ship ANYWHERE"  
317 S. Division  
665-6678



000010444951 F CSO 2180  
DR VICTOR G LATIES  
SCH OF MED  
UNIV OF ROCHESTER BOX EHSC  
ROCHESTER NY 14642